With one new case per 100,000 inhabitants per year, cutaneous T-cell lymphoma (CTCL) is a rare disease. The insidious thing about this incurable blood tumour is that it mainly manifests itself in the skin. Patients suffer from severe itching and develop red patches. It is not uncommon for CTCL to be misdiagnosed, which is all the more fatal because the probability of survival for those affected deteriorates significantly as the disease progresses.
New antibody therapies aim to increase the progression-free survival of CTCL patients and improve their quality of life by alleviating the skin symptoms. Life Science Communication supports the Japanese company Kyowa Kirin in Medical communications.
